Darifenacin interactions
Full monograph for DarifenacinCheck it against another medicine
Medicines
409 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Brexpiprazole | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these… | 5 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Mifepristone | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Posaconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Potassium Chloride | Major | Absorption | Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants… | 15 sources — open the full entry |
| Potassium Citrate | Major | Synergy | Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants… | 15 sources — open the full entry |
| Potassium Citrate + Citric Acid | Major | Synergy | Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants… | 15 sources — open the full entry |
| Sodium Chloride + Potassium Chloride + Sodium Acetate | Major | Absorption | Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants… | 15 sources — open the full entry |
| Tamoxifen Citrate | Major | Metabolism | Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed… | 35 sources — open the full entry |
| Topiramate | Major | Synergy | Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics… | 9 sources — open the full entry |
| Tucatinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Voriconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by… | 7 sources — open the full entry |
| Zonisamide | Major | Synergy | Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics… | 9 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Abiraterone Acetate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Amantadine Hydrochloride | Moderate | Synergy | The anticholinergic-like adverse effects of amantadine may be potentiated by agents with anticholinergic properties such as antihistamines, antispasmodics… | 6 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Metabolism | Coadministration with darifenacin may increase the plasma concentrations of drugs that are metabolized by CYP450 2D6, including many psychotherapeutic drugs… | 2 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Metabolism | Coadministration with darifenacin may increase the plasma concentrations of drugs that are metabolized by CYP450 2D6, including many psychotherapeutic drugs… | 2 sources — open the full entry |
| Amlodipine Besilate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Metabolism · Unknown | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.2 documented mechanisms | 2 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Metabolism · Unknown | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.2 documented mechanisms | 2 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Metabolism · Unknown | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.2 documented mechanisms | 2 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of darifenacin, which has been shown to be a substrate of… | 12 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Aripiprazole | Moderate | Metabolism | Coadministration with darifenacin may increase the plasma concentrations of drugs that are metabolized by CYP450 2D6, including many psychotherapeutic drugs… | 2 sources — open the full entry |
| Artemether + Lumefantrine | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.2 documented mechanisms | 4 sources — open the full entry |
| Asciminib | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Asenapine Maleate | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Atomoxetine Hydrochloride | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 2D6 may increase the plasma concentrations of atomoxetine, which is primarily metabolized by the… | 3 sources — open the full entry |
| Atropine Sulfate (Injection) | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.2 documented mechanisms | 2 sources — open the full entry |
| Betamethasone + Clotrimazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Bethanechol Chloride | Moderate | Antagonism | Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may… | 2 sources — open the full entry |
| Bicalutamide | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Bimatoprost + Timolol | Moderate | Metabolism | Coadministration with darifenacin may increase the plasma concentrations of drugs that are metabolized by CYP450 2D6. The mechanism is decreased clearance due… | 6 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
Food & lifestyle
grapefruit juice
MinorMetabolism
The consumption of grapefruit juice may be associated with increased plasma concentrations of darifenacin. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.
What to do: Concomitant use of Darifenacin with grapefruit or grapefruit juice should generally be avoided.
1 source
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Conditions
Conditions in which Darifenacin needs care, as documented in this source.
Gastrointestinal Diseases
MajorDarifenacin is contraindicated in patients with gastric retention. Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.
1 source
- "Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc. (2017):
Glaucoma
MajorDarifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma. It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.
1 source
- "Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc. (2017):
Urinary Retention
MajorDarifenacin is contraindicated in patients with urinary retention. Darifenacin is a competitive muscarinic receptor antagonist. It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.
1 source
- "Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc. (2017):
Central Nervous System Diseases
ModerateDarifenacin is associated with anticholinergic central nervous system (CNS) effects. Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased. It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects. Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.
1 source
- "Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc. (2017):
Liver Diseases
ModerateDarifenacin is extensively metabolized by the liver following oral dosing. The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B). Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population. No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).
1 source
- "Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc. (2017):
Therapeutic duplication
Drug classes that overlap with Darifenacin, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Chlorpheniramine/methscopolamine/phenylephrine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Urolet mb
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Phosphasal
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Glycopyrrolate/indacaterol
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Sympak ii
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Librax
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Motofen
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Trelegy ellipta
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Butabarbital/hyoscyamine/phenazopyridine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): B & o supprettes
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Hyoscyamine/phenyltoloxamine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Duaklir pressair
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Duodote
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Budesonide/formoterol/glycopyrrolate
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Tussigon
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Albuterol/ipratropium
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Vi-atro
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Anoro ellipta
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Glycopyrrolate/neostigmine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Prosed ds
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Phenohytro
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Formoterol/glycopyrrolate
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Olodaterol/tiotropium